SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Duke Kahanamoku — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientDuke Kahanamoku
Date of birth1890-08-24
IdentifiersMRN HR-ML050-SYN-TD; SSN (made up) 000-50-6847
Document date1957-04-13
AuthorKawika Lindgren-Morrison, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week review after starting sacubitril-valsartan, carvedilol and empagliflozin. [S]

History of Present Illness

Mr. Kahanamoku returns two weeks after starting carvedilol and empagliflozin and twelve days after his first dose of sacubitril-valsartan, taken as planned 36 hours after the last lisinopril. He feels better: he walks up the slope near his office without stopping, the ankle swelling has gone, and he sleeps flat. He has had no lightheadedness, cough, genital itching or burning on passing urine. His home weight is steady at 93.5 to 94 kg. Coronary angiography last week showed an old complete blockage of the main artery at the front of the heart, with collaterals, and only mild narrowing elsewhere; the cardiologist advised that opening it would not help the scarred muscle. He is ready for the second iron infusion. [S]

ElementDetail
FunctionWalks uphill without stopping; NYHA class II to III
Medicine effectsNo lightheadedness, cough or genital infection
AngiographyChronic total occlusion of the proximal left anterior descending artery; mild disease elsewhere; no revascularization
KCCQ-1256, from 38

Review of Systems

SystemResultFinding
CardiovascularNegativeNo chest pain, palpitations, ankle swelling or lightheadedness
RespiratoryNegativeNo cough; sleeps flat
GenitourinaryNegativeNo genital itching or dysuria

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Aspirin 81 mg delayed-release oral tablet, one tablet dailyOne tablet dailyOral route1952-06-21activeS
Atorvastatin 40 mg oral tablet, one tablet dailyOne tablet dailyOral route1952-06-21 to 1957-03-16completedS
Atorvastatin 80 mg oral tablet, one tablet dailyOne tablet dailyOral route1957-03-16activeS
Metoprolol tartrate 25 mg oral tablet, one tablet twice dailyOne tablet twice dailyOral route1952-06-21 to 1957-03-30completedS
Lisinopril 10 mg oral tablet, one tablet dailyOne tablet dailyOral route1952-06-21 to 1957-03-30completedS
Furosemide 40 mg oral tablet, one tablet every morningOne tablet every morningOral route1957-03-16 to 1957-04-27completedS
Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet twice daily, first dose 36 hours after the last lisinoprilOne tablet twice dailyOral route1957-03-30 to 1957-09-28completedS
Carvedilol 3.125 mg oral tablet, one tablet twice daily with food, starting the evening after the last metoprolol tartrateOne tablet twice daily with foodOral route1957-03-30 to 1957-04-13completedS
Carvedilol 6.25 mg oral tablet, one tablet twice daily with foodOne tablet twice daily with foodOral route1957-04-13 to 1957-04-27completedS
Empagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating or drinkingOne tablet daily, with sick-day rulesOral route1957-03-30activeS
Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) dailyOne-half tablet dailyOral route1957-04-13activeS
Ferric carboxymaltose 750 mg (15 mL vial, 50 mg/mL) by intravenous infusion, two doses two weeks apartTwo infusions two weeks apartIntravenous route1957-03-30 to 1957-04-13completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1957-04-13Body height185cmS
1957-04-13Body weight93.6kgS
1957-04-13Body mass index (BMI) [Ratio]27.3kg/m2S
1957-04-13Systolic blood pressure118mm[Hg]S
1957-04-13Diastolic blood pressure72mm[Hg]S
1957-04-13Heart rate74/minS
1957-04-13Respiratory rate16/minS
1957-04-13Body temperature36.6CelS
1957-04-13Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1957-04-13Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
1957-04-13Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
1957-04-13Creatinine [Mass/volume] in Serum or Plasma1.16mg/dL0.74-1.35 mg/dLNormalS
1957-04-13Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1952)/1.73 sq M69mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1957-04-13Glucose [Mass/volume] in Serum or Plasma96mg/dL70-99 mg/dLNormalS
1957-04-13Magnesium [Mass/volume] in Serum or Plasma2mg/dL1.6-2.6 mg/dLNormalS
1957-04-13Overall summary score [KCCQ-12]56{score}S

Physical Exam

Vital signs recorded on 1957-04-13; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 118/72, pulse 74; weight 93.6 kg
NeckJugular venous pressure not raised
CardiovascularRegular rhythm; no S3; apical systolic murmur
RespiratoryClear
ExtremitiesNo edema; right radial access site healed

Problems

ProblemClinical statusVerificationCodeProvenance
Breathlessness on exertion for six weeks (paddling out, walking uphill, finishing his morning swim), with ankle swelling by evening and tiredness, five years after a heart attack; cause to be determinedresolvedconfirmed R06.09S — Synthetic presenting problem, resolved at the second visit when the echocardiogram and cardiology established heart failure with reduced ejection fraction.
Coronary artery disease with an old anterior myocardial infarction five years ago, treated with medicines; synthetic modern episode linked to the documented heart attack of 1883activeconfirmed I25.2S — Synthetic modern diagnosis; the 1952 heart attack remains D in the history.
Heart failure with reduced ejection fraction from ischemic cardiomyopathy (ejection fraction 30% with a thinned, akinetic anterior wall and apex), NYHA class III at diagnosisactiveconfirmed I50.22S — Synthetic modern diagnosis made at the second visit; no claim that he had heart failure in his lifetime.
Iron deficiency without anemia (ferritin 62 ng/mL, transferrin saturation 16%)activeconfirmed E61.1S — Synthetic finding at the heart failure workup.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationBlood pressure and heart rate (seated and standing)Every visitCompleted today118/72 mmHg, pulse 74; no orthostatic drop
ExaminationWeight, volume status (jugular venous pressure, edema, lungs) and NYHA classEvery visitCompleted today93.6 kg; jugular venous pressure not raised; lungs clear; no edema; NYHA II to III
LaboratoryMetabolic panel (sodium, potassium, creatinine and eGFR) and magnesiumOne to two weeks after starting or changing a diuretic, ARNI, MRA or SGLT2 inhibitor; then every three to six monthsCompleted todayAbout two weeks after sacubitril-valsartan and empagliflozin: sodium 137, potassium 4.5, creatinine 1.16 mg/dL (eGFR 69), magnesium 2.0
Medication safetyGuideline-directed medical therapy: ARNI, evidence-based beta-blocker, MRA and SGLT2 inhibitor, toward target dosesEvery two weeks during titrationCompleted todayAll four classes now started: spironolactone added and carvedilol raised today
Medication safetySGLT2 inhibitor and ARNI: genital infection, volume depletion, hypotension and angioedemaEvery visitCompleted todayNone; sick-day rules reviewed
SurveyKCCQ-12 heart failure health statusAt diagnosis, then every three to six monthsCompleted today56, from 38
ImagingIschemic evaluation (coronary angiography)At diagnosis of HFrEF with suspected coronary causeUp to dateDone last week: chronic total occlusion of the proximal left anterior descending artery, mild disease elsewhere; no revascularization
ImagingEchocardiogramAt diagnosis; repeat after three to six months of optimized therapy for device decisions, or with unexplained changeNot indicatedDiagnosis two weeks ago; repeat after three to six months of optimized therapy
Medication safetyIron studies (ferritin, transferrin saturation) and intravenous ironAt diagnosis; after repletion and about yearlyCompleted todaySecond ferric carboxymaltose 750 mg infusion today
ExaminationPrimary-prevention ICD evaluation (and CRT if QRS is wide)After at least 90 days of optimized therapy, and at least 40 days after a myocardial infarctionDueAfter at least 90 days of optimized therapy
ReferralCardiac rehabilitation for heart failureWhen eligible: ejection fraction 35% or below, NYHA II to IV, six weeks of stable therapy and no procedure in six weeksDueEligible from about six weeks after angiography and the last medicine start
Self-managementSelf-care: daily weights, sodium, sick-day rules and symptoms to reportEvery visitCompleted todayWeighs daily; less salted fish and shoyu; sick-day card given
Self-managementCulturally safe care: ʻohana involvement as he chooses; his own healing practicesEvery visitCompleted todayHe reviews decisions with his ʻohana at home as he chooses

Goal progress:

Guideline basis: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction (2024); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, heart failure and ischemic heart disease monographs (2026)

Follow-up: Review in two weeks with a metabolic panel (two weeks after spironolactone), a lipid panel and the KCCQ-12. Call for lightheadedness, vomiting or diarrhea (sick-day rules), or a weight change beyond the plan. Next scheduled visit 1957-04-27: two-week review, five days after the sick visit: kidney function and potassium, medicine doses, lipids, and cardiac rehabilitation adapted to the ocean. [S]